Smart Biosensing Technologies for Early Detection of Metabolic Disorders

Erscheinungsjahr 2026
ISBN: 978-0-443-45911-5
Verlag: Elsevier Science Publishing Co Inc

Buch, Englisch, 400 Seiten, Format (B × H): 216 mm x 276 mm

Smart Biosensing Technologies for Early Detection of Metabolic Disorders gives a clear overview of the latest biosensor tools that help detect and monitor metabolic diseases like diabetes, obesity, and insulin resistance early. It explains how these sensors work using basic science and shows new wearable, non-invasive, and easy-to-use devices. This book is useful for researchers, doctors, and professionals working in healthcare technology. This book connects research from different fields to help solve real problems in making and using biosensors. It includes examples of how these sensors are used, new markers for disease detection, and how AI and digital health can improve care. Readers will learn how to develop better diagnostic tools and improve treatment for metabolic diseases.

Autoren/Hrsg.

Rehman, Kanwal

Fachgebiete

• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Naturwissenschaften Physik Angewandte Physik Biophysik
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Physiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie

Inhaltsverzeichnis

Section I: Foundations of biosensing and metabolic disorders
1. Detecting the preclinical window in metabolic disorders: Biomarkers, biosensors, diagnostic challenges, and translational opportunities
2. Multi-omic biomarkers and biosensors for metabolic disorders: Discovery to clinical translation
3. Metabolic biosensing technologies: Biophysical foundations, transduction strategies, and clinical translation

Section II: Emerging biosensing platforms for biomarker detection
4. Nanomaterials for metabolic biosensing: Interfacial biophysics, analytical performance, and clinical translation
5. Microfluidic and paper-based biosensing technologies for metabolic disorders: From sample processing to clinical translation
6. Wearable optical and electrochemical biosensors for continuous metabolic monitoring: Principles, system integration, and clinical translation

Section III: Smart and intelligent biosensing approaches
7. Artificial intelligence and machine learning for metabolic biosensors: From data analytics to clinical deployment
8. Cloud—edge architectures for connected metabolic care: IoMT integration, interoperability, analytics, and lifecycle management
9. Continuous wearable and implantable biosensors for metabolic disorders: From biosensing technologies to clinical translation

Section IV: Applications in early detection of specific metabolic disorders
10. Smart biosensing technologies for diabetes mellitus: From biomarker discovery and sensor design to clinical validation and real-world deployment
11. Multimodal biosensing and continuous phenotyping for obesity and metabolic syndrome: Biomarkers, sensor systems, and clinical translation
12. Translational cardiometabolic biosensing integrating biomarkers, multiplex panels, sensing strategies, and clinical validation
13. Multi-omic biomarkers, biosensing technologies, and precision diagnostics for rare and inherited metabolic disorders
14. Advanced biophysical biosensing strategies for monitoring oxidative stress and inflammation in metabolic disorders

Section V: Translational perspectives and future directions
15. Translating smart biosensors for metabolic health: Regulatory pathways, ethical governance and commercialization strategy

Über Autor(innen)

Rehman, Kanwal
Dr. Kanwal Rehman is working as an Associate Professor at the Department of Pharmacy in The Women University, Multan, Pakistan. Dr. Rehman received her PhD in Pharmacology from Zhejiang University, China. She nurtures
a keen interest in the pathogenesis of metabolic disorders and new therapeutic modalities for its treatment. Currently, she
is focusing on the investigation of the role of pharmacogenomics based upon gene polymorphism on various molecular and
metabolic pathways that are involved in mitogenic disorders and treatment strategies, like natural biogenic compounds against different risk factors of metabolic disorders, including pancreatitis, cardiometabolic disorders, and hormonal imbalance. Dr. Rehman has also been awarded the Research Productivity Award by the Pakistan Council for Science and Technology, Pakistan; the PAS Gold Medal from the Pakistan Academy of Sciences; and the A.R. Shakoori Gold Medal from the Zoological Society of Pakistan.